Mapping Endothelial-Macrophage Interactions in Diabetic Vasculature: Role of TREM2 in Vascular Inflammation and
Abstract:
Diabetes mellitus (DM) significantly accelerates vascular diseases like peripheral arterial disease (PAD). Endothelial cells (ECs) and macrophages (MΦs) singularly and synergistically are important contributors to DM-associated vascular dysfunction. Single-cell (sc) profiling technologies are revealing the true heterogeneity of ECs and MΦs, but how this cellular diversity translates to cell-cell interactions, and consequentially vascular function, remains unknown. We leveraged scRNA sequencing and spatial transcriptome (ST) profiling to analyze human mesenteric arteries from non-diabetic (ND) and type 2 diabetic (T2D) donors. We generated a transcriptome and interactome map encompassing the major arterial cells and highlighted Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) as a top T2D-induced gene in mononuclear phagocytes (MPs), with concomitant increases of TREM2 ligands in ECs. We verified DM-associated TREM2 induction in cell and mouse models, and found that TREM2 inhibition decreases pro-inflammatory responses in MPs and ECs, as well as increases EC migration in vitro. Furthermore, TREM2 inhibition using a neutralizing antibody enhanced ischemic recovery and flow reperfusion in DM mice subjected to hindlimb ischemia, suggesting that TREM2 promotes ischemic injury in DM. Finally, in human PAD, co-existing DM was associated with greater expression of TREM2 and its interaction with ECs, with a further increase in ischemic tissue compared to patient-matched non-ischemic tissue. Collectively, our study presents the first atlas of human diabetic vessels with single cell and spatial resolution, and identifies TREM2-EC interaction as a key driver of diabetic vasculopathies, the targeting of which may offer an opportunity to ameliorate vascular dysfunction associated with DM-PAD.
Insights
Diabetes mellitus accelerates vascular disease by altering cell interactions. Targeting the TREM2-endothelial cell pathway shows promise for treating diabetic vascular dysfunction and peripheral arterial disease.
Area of Science:
- Vascular biology
- Immunology
- Genomics
Background:
- Diabetes mellitus (DM) exacerbates vascular diseases, including peripheral arterial disease (PAD).
- Endothelial cells (ECs) and macrophages (MΦs) play critical roles in DM-associated vascular dysfunction.
- Understanding cellular heterogeneity and interactions is key to addressing DM-related vascular issues.
Purpose of the Study:
- To create a detailed map of cellular interactions in diabetic human mesenteric arteries.
- To identify key molecular pathways driving vascular dysfunction in type 2 diabetes (T2D).
- To investigate the role of Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) in diabetic vasculopathy.
Main Methods:
- Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) on human mesenteric arteries from non-diabetic (ND) and T2D donors.
- Analysis of gene expression and cell-cell interactions.
- In vitro and in vivo validation using cell models, mouse models, and human PAD tissues.
Main Results:
- A comprehensive transcriptome and interactome map of major arterial cells in ND and T2D vessels was generated.
- TREM2 was identified as a T2D-induced gene in mononuclear phagocytes (MPs), with increased ligands in ECs.
- TREM2 inhibition reduced inflammation, enhanced EC migration, improved ischemic recovery in DM mice, and was upregulated in human PAD.
Conclusions:
- This study provides the first single-cell and spatial atlas of human diabetic vessels.
- The TREM2-endothelial cell interaction is a critical driver of diabetic vasculopathies.
- Targeting TREM2 presents a potential therapeutic strategy for ameliorating vascular dysfunction in DM-PAD.
More Related Videos
05:51Characterization of a Novel Human Organotypic Retinal Culture Technique
Published on: June 9, 2021
09:42Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
Published on: June 26, 2019
